A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced by ‘on-target/off-tumor’ binding to PD-L1 widely...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer, Wijnand Helfrich
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-08-01
Subjects:	bispecific antibody egfr immunotherapy pd-l1
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1466016